Symbiotec Pharmalab Ltd

NSE: SYMBIOTEC · BSE: 544889 · Pharmaceuticals & Biotechnology · 18 announcements

Share price: ₹1,611.00
Market cap: ₹10,352 Cr
Revenue (annual): ₹869.1 Cr
Net profit (annual): ₹109.9 Cr
Promoter holding: 33.28%
FII holding: 3.79%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 2 Results Update 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

2 announcements with these filters

6 Nov 2026 10:43 IST NSE

Earnings Call

Symbiotec Pharmalab Earnings Call Transcript: Key Takeaways

Q2 FY27 revenue ₹280 Cr (+43%) and EBITDA ₹94 Cr (+88%) were flattered by a ₹53 Cr one-time DCV milestone. Management sounds confident, but pricing and timing answers stayed unquantified.

Call: Guides 20% growth

Open call summary → Read the filing ↗

5 Nov 2026 20:20 IST BSE

Earnings Call

Symbiotec Pharmalab Investor Presentation: Key Takeaways

Q2 FY27 revenue ₹280 Cr (+43%), PAT ₹52 Cr (+169%); H1 revenue ₹498 Cr (+25%), PAT ₹66 Cr (+34%). Capex-led push into DCV injectables and CDMO.

Open call summary → Read the filing ↗